ICAM-1

ICAM-1

ICAM-1 Overview

Molecule Name
Intercellular adhesion molecule-1
Synonyms
ICAM1,BB2,CD54,P3.58
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs2
Highest Development StageApproved
Target Synonym
Intercellular Adhesion Molecule 1,Cell Surface Glycoprotein P3.58,Major group rhinovirus receptor,Human Rhinovirus Receptor,CD54 Antigen,P3.58,CD54,BB2,Intercellular Adhesion Molecule-1,ICAM1,ICAM-1,Intercellular Adhesion Molecule 1 (CD54), Human Rhinovirus Receptor,Epididymis Secretory Sperm Binding Protein
Background
Inter-Cellular Adhesion Molecule 1 (ICAM-1) is also known as Cluster of Differentiation 54 (CD54), is a member of the immunoglobulin superfamily, and is a cell surface glycoprotein which is typically expressed in low concentrations on endothelial cells and cells of the immune system. The protein encoded by this gene is a type of intercellular adhesion molecule continuously present in low concentrations in the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFα) and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 is a ligand for LFA-1 (integrin), a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via ICAM-1/LFA-1 and then transmigrate into tissues. ICAM-1 has been implicated in subarachnoid hemorrhage (SAH). Levels of ICAM-1 are shown to be significantly elevated in patients with SAH over control subjects in many studies. ICAM-1 expressed by respiratory epithelial cells is also the binding site for rhinovirus, the causative agent of most common colds.

ICAM-1 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CinainuPhase 3 ClinicalLegacy Healthcare (Switzerland) Sa
Alopecia Areata
Details
GebasaxturevV-937; CVA-21Phase 2 ClinicalViralytics Ltd
Breast Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Prostatic Neoplasms; Urinary Bladder Neoplasms
Details
AIC-100AIC-100Phase 1 ClinicalAffyimmune Therapeutics Inc, National Cancer Institute
Oncocytic cell carcinoma of the thyroid; Thyroid Carcinoma, Anaplastic
Details
68Ga-ICAM-1pepPhase 1 ClinicalBeijing Cancer Hospital
Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Tocopherol acetateDSE-9912ApprovedNational Institute Of Diabetes And Digestive And Kidney DiseasesEphynal, Aquasol EJapanVitamin E Deficiency; Diabetic Retinopathy; Atherosclerosis; Intermittent Claudication; Venous Thromboembolism; ThrombosisEisai Co Ltd1951-09-01
Atherosclerosis; Diabetic Retinopathy; Intermittent Claudication; Metabolic Dysfunction-Associated Steatotic Liver Disease; Thrombosis; Venous Thromboembolism; Vitamin E Deficiency
Details
Ascorbic Acid/Biotin/Cholecalciferol/Cyanocobalamin/Dexpanthenol/Folic acid/Niacinamide/Pyridoxine/Riboflavin/Thiamine/Tocopherol Acetate/Vitamin A/Vitamin KApprovedSandoz Canada IncInfuvite PediatricUnited StatesAvitaminosisSandoz Canada Inc2001-02-21
Avitaminosis
Details